Study of new drug combination for HER2-positive breast cancer with PIK3CA mutation
Part of Cancer, Skin clinical trials.
This trial tests a combination of drugs before surgery for early-stage HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). The treatment aims to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage breast cancer that has not spread and is HER2-positive and PIK3CA-mutated.
- You are at least 18 years old.
- You have not had prior treatment for this breast cancer.
- You are generally healthy with good heart, liver, kidney, and blood function.
- You can have a biopsy to confirm the cancer and its markers.
- You are willing to use effective contraception if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
This study looks at how well a drug called inavolisib works when combined with hormone therapy for people with a certain type of advanced breast cancer that has a specific gene change (PIK3CA). It aims to see if this treatment helps control the cancer in real-world settings.
This trial tests a combination of three targeted therapies (inavolisib, ribociclib, and fulvestrant) in people with a specific type of advanced breast cancer that has a PIK3CA genetic change. The goal is to see if this new combination can shrink tumors or slow cancer growth, potentially offering a new option before other treatments are needed.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.